ArticleJournal of neurology2026
Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune-mediated necrotizing myopathy (IMNM) is a distinct entity with limited large-cohort data. We aimed to characterize clinico-serological features and treatment outcomes of anti-SRP, anti-HMGCR, and seronegative IMNM in a large Italian cohort.
methodsRetrospective multicenter study of adults diagnosed with IMNM (224th ENMC criteria) across 14 Italian neuromuscular centers between 2019 and 2022 was performed.
resultsWe included 159 subjects (57% female, median age 62 years): 40 SRP+, 71 HMGCR+, 41 seronegative, and 7 untested. SRP+ more frequently presented with proximal upper limb weakness and axial involvement versus HMGCR+ (OR = 3.89, padj = 0.007, OR = 3.47, padj = 0.04) and seronegative (OR = 4.00, padj = 0.014, OR = 15.2, padj = 0.005). Lung involvement was higher in SRP+ (7.5%), vs none in HMGCR+ and 2.4% in seronegative (p=0.028). Extramuscular features were more frequent in HMGCR+ (OR = 3.78, p = 0.019, padj = 0.057). SRP+ had higher odds of loss of motor independence (OR=4.22, padj =0.011) and relapse (OR = 14.4, padj = 0.010) than HMGCR+. Seronegative had better functional outcomes than SRP+ (p=0.047). Cancer associated myositis predicted worse disability (OR = 6.93, p = 0.0044). Overall, 71.7% improved with corticosteroids (OR=3.83, padj =0.01) and immunosuppressants (OR=2.296, padj =0.037), without serotype differences. CK decreased in 81.8% and normalized in 40.3% of patients; ΔCK was associated with improvement (p=0.017), clinical remission (p=0.002) and correlated with post-treatment functional scores (R=0.19, p= 0.044).
conclusionSubtype-specific differences and prognostic factors emerge. Exploratory functional assessment and ΔCK may capture treatment response in real-world settings.
Indexed as
Identifiers
42671644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.